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Drug ligand bindingns are attributed to the peripheral-type benzodiazepine receptor (PBR) recently
renamed translocator protein (TSPO). The best characterized function is the translocation of cholesterol from
the outer to inner mitochondrial membrane, which is a rate-determining step in steroid biosynthesis. TSPO
drug ligands have been shown to stimulate pregnenolone formation by inducing TSPO-mediated translocation
of cholesterol. Until recently, no direct structural data on this membrane protein was available. In a previous
paper, we showed that a part of themouse TSPO (mTSPO) C-terminal region adopts a helical conformation, the
side-chain distribution of which provides a groove able to ﬁt a cholesterol molecule. We report here on the
overall structural properties of mTSPO. This study was ﬁrst undertaken by dissecting the protein sequence and
studying the conformation of ﬁve peptides encompassing the ﬁve putative transmembrane domains from
1H-NMR data. The secondary structure of the recombinant protein in micelles was then studied using CD
spectroscopy. In parallel, the stability of its tertiary fold was probed using 1H–15N NMR. This study provides
the ﬁrst experimental evidence for a ﬁve-helix fold of mTSPO and shows that the helical conformation of
each transmembrane domain is mainly formed through local short-range interactions. Our data show that, in
micelles, mTSPO exhibits helix content close to what is expected but an unstable tertiary fold. They reveal
that the binding of a drug ligand that stimulates cholesterol translocation is able to stabilize the mTSPO
tertiary structure.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionSince 1977, binding sites for benzodiazepines have been reported
outside the central nervous system [1]. The peripheral-type benzo-
diazepine receptor (PBR) responsible for this binding was recently
renamed translocator protein (18-kDa; TSPO) in agreement with its
endogenous biological functions [2]. Among its functions, the
cholesterol transport across the outer membrane of mitochondria is+33 1 69 08 81 39.
A, N,N-diisopropylethylamine;
HATU, 1-[bis(dimethylamino)
orophosphate; HSQC, hetero-
rhauser enhancement spectro-
noxy)valeric acid-polyethylene
l rights reserved.the best characterized [3]. Various TSPO ligands, such as the en-
dogenous diazepam binding inhibitor, and the exogenous (2-chlor-
ophenyl)-N-methyl-N-(1-methyl-propyl)-3-isoquinoline carboxa-
mide (PK 11195) have been described as stimulating this transport
[2]. Direct evidence for cholesterol binding with nanomolar afﬁnity
to mTSPO has been obtained from in vitro experiments performed
on recombinant protein reconstituted in proteoliposomes [4]. Until
recently, no experimental structural data on the mTSPO structure was
available. The ﬁve-helix fold published models were established using
a topological analysis based on biochemical results [5], secondary
structure predictions and bacteriorhodopsin as a template [6,7]. In
these models, TSPO is able to accommodate a cholesterol molecule in
the space delineated by the helices in agreement with the function of
cholesterol transport across the outer membrane of mitochondria. In a
previous paper [8], functional data obtained on recombinant mTSPO
combined with structural data obtained on the C-terminal domain
revealed a putative cholesterol binding groove and indicated essential
residues involved in cholesterol binding. Based on the comparison of
Fig. 1. Titration of PK 11195. A) 1H chemical shift variations (Δδ) of the most sensitive
aromatic signal of PK 11195 as a function of DPC concentration. B) Variations of ab-
sorbance at 285 nm (ΔA285) of a solution of 0.075 mM PK 11195 in 10 mMNa phosphate
buffer (pH 6.0 at room temperature) as a function of DPC concentration. See Materials
and methods for additional details.
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volvement of other transmembrane helices in the cholesterol binding
site. Therefore, a detailed structural study of TSPO is required to fully
describe uptake and translocation of cholesterol into the mitochon-
dria. Here, we report on the ﬁrst experimental data on the overall
secondary structure of mTSPO and on the stability of its tertiary fold in
micelles.
2. Materials and methods
2.1. Peptide synthesis and puriﬁcation
Peptides P1 to P5 with the sequences in Table 1 were used for this work. The
peptides were designed longer than the amino acid sequence of the hydrophobic
domains for solubility reasons. Synthesis and puriﬁcation of P2 were carried out at the
Pasteur Institute (Y.-M. C.) according to the Fmoc/tBu solid-phase strategy [9]. Brieﬂy,
the peptide was synthesized from a Fmoc-PAL-PEG-PS resin on a Pioneer continuous-
ﬂow peptide synthesizer, using 4-fold molar excess of amino acid derivatives with
HATU/DIPEA as coupling reagent and double coupling cycles. Both apparatus and
chemicals were obtained from Applied Biosystems (Foster City, CA, USA), except for
piperidine used for Fmoc deprotectionwhich was purchased from Sigma. Crude P2 was
dissolved with a mixture of aqueous triﬂuoroacetic acid (pH 2)/acetonitrile (25%) and
directly puriﬁed by reverse-phase MPLC on a preparative column packed with 300 Å
20 μm C4 Nucleoprep (Macherey-Nagel GmbH & Co, Düren, Germany), by applying a
linear gradient (0.8%/min) of acetonitrile (initial content of 25%) in 0.08% aqueous
triﬂuoroacetic acid over 60 min at a 20 ml/min ﬂow rate. The purity of the ﬁnal peptide
(above 95%) was checked by HPLC. The puriﬁed peptide was quantiﬁed by amino acid
analysis (total yield 16%) and ﬁnally characterized by positive ion electrospray ioni-
sation mass spectrometry. The experimental data were consistent with the expected
mass: 3231.5 (expected, 3231.8).
P1 and P4were chemically synthesized by Biosynthesis Laboratories (Lewisville, TX,
USA), P3 by NeoMPS (Strasbourg, France) and P5 by GL Biochem Ltd (Shanghai, China).
All peptides were puriﬁed to N90% as judged by high-performance liquid chromatogra-
phy andwere further characterized bymass spectrometry: P12808.0 (expected, 2811.3),
P3 3276.7 (expected, 3276.9), P4 3069.2 (expected, 3067.6), and P5 3592.4 (expected,
3590.2).
2.2. Recombinant protein expression and puriﬁcation
The expression and puriﬁcation of the recombinant protein were performed as
previously described for unlabelled protein [4,8,10] with minor modiﬁcation since
sodium dodecyl sulfate (SDS) was exchanged by deuterated dodecylphosphocholine
(DPC-d38) before protein elution fromNTA-Ni column (Qiagen, Les Ulis, France). Stable-
isotope labelled recombinant mTSPOwas expressed utilizing established protocols [11].
2.3. PK 11195
The PK 11195 was purchased from Sigma. Its purity is greater than 99% as judged by
thin layer chromatography (data from Sigma) and has been further checked by 1H and
13C NMR spectra recorded in deuterated methanol. Solubility of PK 11195 in 10 mM
sodium phosphate buffer solutions is limited to 0.1mM as checked byUV absorbance. In
the presence of DPC, the solubility of PK 11195 increases due to intermolecular inter-
actions. The interaction of PK 11195 with DPC in 10 mM sodium phosphate buffer
solutions was characterized by NMR and absorption experiments (Fig. 1). 1D 1H NMR
spectra of a 0.1 mM PK 11195 in 10 mM sodium phosphate buffer in the presence of
increasing amount of DPC yield chemical shift variations (Fig. 1A) for DPC concentration
greater than 0.75 mM and smaller than 2 mM. The absorbance spectrum of PK 11195
changes in the presence of DPC with a maximal variation at 285 nm, when recorded
with an UNICAM (UVII) spectrophotometer. The variation of absorbance at 285 nm for a
solution of 0.075 mM PK 11195 in 10 mM sodium phosphate buffer as a function of
increasing amount of DPC is presented in Fig. 1B. Fig. 1A and B clearly reveals inter-
actions of PK 11195 with DPC: (i) NMR data monitor interactions of monomers of DPCTable 1
Amino acid sequences of the peptides encompassing the hydrophobic domains (in
italic)
Table 1
Amino acid sequences of the peptides encompassing the hydrophobic domains (in
italic)with PK 11195 since changes occur at DPC concentration below published values of cmc
(critical micellar concentration) for DPC which are in the millimolar range (~1.5 mM),
and (ii) absorption data indicate incorporation of PK 11195 molecules in DPC micelles,
since the onset of changes is close to cmc value for DPC.
2.4. Circular dichroism
Far UV circular dichroism spectra were recorded on a Jobin-Yvon CD6 spectro-
polarimeter calibratedwith d-10-camphorsulfonic acid. Measurementswere performed
at room temperature using 0.1 mm path length quartz cuvettes (Hellma) for 40 μM
mTSPO solubilized in 10 mM sodium phosphate buffer solutions, 1.4 mM PK 11195 and
28.5 mM DPC. CD spectra were recorded in the 180 to 260 nmwavelength range with a
0.5 nm step resolution, 2 s signal averaging time and 2 nm bandwidth. Spectra were
averaged over eight scans and corrected for background. The mTSPO concentration was
determined by measuring the UV absorbance at 280 nm using appropriate extinction
coefﬁcients for Trp and Tyr residues [12]. A consensus secondary structure content was
estimated by spectral deconvolution using CONTINLL and CDSSTR software and the data
sets of reference proteins SMP50 (37 soluble proteins and 13 membrane proteins) and
SP37 (37 soluble proteins) [13]. An estimated error of 5% has been found in the evalu-
ation of the percentage of helical secondary structure as a consequence of the error in the
evaluation of the concentration of the protein and of the different methods of decon-
volution and data sets of reference proteins used for the analysis of the circular dich-
roism spectra.
2.5. NMR experiments
Peptides P1 (1.5 mM), P2 (1.5 mM) and P4 (0.6 mM) were solubilized in 50 mM
phosphate buffer (pH 6) 90:10 H2O:D2O solutions containing 200 mM DPC-d38.
P3 and P5 (0.6 mM) were solubilized in a 4:4:1 CDCl3:CD3OH:H2O solution. NMR
experiments were performed at 25 and 35 °C on a Varian INOVA spectrometer
operating at 800 MHz 1H frequency, equipped with a cryogenic triple resonance
probe. Chemical shifts were referenced to internal standard DSS. Standard TOCSYand
NOESY spectra were recorded at 25 and 35 °C with mixing times of 70 ms (TOCSY),
80 and 160 ms (NOESY) for the peptide samples. Water suppression was achieved
using excitation sculpting [14]. Signal assignment was performed using the standard
Fig. 2. TSPO amino acid sequences. Amino acid sequences alignment of the TSPO from mouse (accession number P50367), rat (P16257), human (P30536), bovine (P30535), sheep
(Q9GMC9) and rainbow trout (Q7ZZV7). Alignment was made using CLUSTAL W (1.83) computer program. Conserved residues in all species are shown as hyphens. Hydrophobic
residues forming a quasicontinuous set of at least 20 amino acids are shown in red.
Fig. 3. Sequential and medium range NOEs involving the backbone protons of the P1 to P5 peptides. P1, P2 and P3 peptides were solubilized in buffered DPC micelles, P3 and P5 in
organic solvent. See Materials andmethods for additional details. The bar thickness refers to the NOE intensity (strong, medium, and weak). Grey bar corresponds to ambiguous NOE.
The NOE were obtained from 800 MHz NOESY spectra (mixing time 160 ms) recorded at 25 °C.
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Table 2
NMR-derived restraints and structural statistics of the 10 selecteda structures of peptides P1 to P5
P1 P2 P3 P4 P5
Experimental NMR constraints
Number of NOE distance constraints 418 323 287 286 326
Intraresidue 214 168 172 172 178
Sequential 103 83 57 55 74
Medium rangeb 92 64 54 57 70
Long rangec 0 1 0 0 0
Ambiguous 9 7 4 2 4
Number of NOE distance
constraints violations
Violations greater than 0.1 Å 3–6 0–4 2–6 0–2 0–5
Violations greater than 0.3 Å 1 0 1 0 0
Violations greater than 0.5 Å 0 0 1 0 0
Rmsd from the mean structure
All residues backbone atoms 1.29 Å 1.26 Å 3.15 Å 1.91 Å 0.90 Å
Residues in helical regions (6–24) 0.77 Å (50–70) 0.71 Å (79–94) 0.40 Å (104–115) 0.70 Å (137–160) 0.51 Å
(118–129) 0.62 Å
Ramachandran statisticsd
Residues in most favoured region 86.1% 85.2% 80.4% 90% 96.8%
Residues in additional allowed region 11.1% 12.9% 15.8% 9.6% 2.8%
Residues in generously allowed region 0.6% 0% 0.8% 0% 0%
Residues in disallowed region 2.2% 1.9% 2.9% 0.4% 0.4%
a See Materials and methods.
b Medium range involved residues separated by 2 to 4 residues.
c Long range involved residues separated by more than 4 residues.
d As determined by PROCHECK-NMR.
1378 S. Murail et al. / Biochimica et Biophysica Acta 1778 (2008) 1375–1381protocol [15]. 2D 1H, 15N-HSQC spectra were recorded on 0.2 mM mTSPO samples in
10 mM sodium phosphate buffer (pH 6) 90:10 H2O:D2O solutions containing 140 mM
DPC-d38, 7 mM PK 11195 at 30 °C on a Bruker DRX 600 MHz spectrometer equipped
with a cryogenic triple resonance probe.
2.6. Structure calculation
The cross-peak intensities in the NOESY spectra recorded at 800 MHz with a
160 ms mixing time were measured and partially assigned within Sparky [T.D.
Goddard and D.G. Kneller, University of California, San Francisco]. These NOEs, along
with a table of chemical shifts, were used as input to the software ARIA (Ambiguous
Restraints for Iterative Assignment, version 2.2) [16]. Ambiguous αN medium range
NOEs were also used as input to the software ARIA providing that they were con-
sistent with αβ (i, i+3) NOE network. The calculations were performed starting from
random templates, using two different protocols: with no upper bound corrections
(standard ARIA protocol) and with an upper limit of 6 Å for the proton–proton
distance restraints derived from the NOE cross peaks has been used. After 7 iterations
of standard ARIA structure calculation, an ensemble of 100 structures was calculated.
Satisfactory results were obtained with the protocol using an upper limit of 6 Å for all
the peptides and with the protocol with no upper bound corrections only for the P3
peptide. The 20 lowest energy conformers were further energy-minimized using
CHARMM 29 [17]. Since the difference in energy between the minimized structures
was found to be quite small (less than 10%), a ﬁnal set of 10 best structures has been
selected on the basis of the minimum root mean-square deviation (rmsd) from the
mean structure. Structure quality and Ramachandran plots have been investigated
using PROCHECK-NMR [18,19]. Rmsds have been calculated using the rmsd tool of the
VMD software [20].
3. Results
3.1. NMR conformational studies of mTSPO peptides
Amino acid sequences of TSPO from various species (Fig. 2) have a
high degree of homology (80%) [21]. Five regions containing a quasi-
continuous set of consecutive hydrophobic residues (indicated in red)
appear as good candidates to form transmembrane (TM) helices. These
hydrophobic regions have a 20–22 residues length which is in agree-
ment with the average size required to span the hydrophobic core of a
bilayer [22]. These regions are conserved within the TSPO sequences
of the various species. In addition, the majority of the polar residues
found in the corresponding sequences are threonines and serines,
frequently present in transmembrane helices. Finally, except for the
third region, the putative transmembrane sequences have a trypto-phan at the end, a residue known for its frequent location in the
interfacial region of the lipid bilayer [23,24].
To study the structural propensity of the amino acid sequence to
form helical structures, ﬁve peptides (named P1 to P5, Table 1) encom-
passing each of the ﬁve hydrophobic regions were synthesized and
their conformational properties were studied by NMR. Deuterated
dodecylphosphocholine (DPC) micelles were used as membrane like
environment to solubilize synthetic peptides. However, in the pre-
sence of micelles, P3 and P5 tend to aggregate as judged from the
unusual broad linewidths of their NMR signals. In both cases, the use of
a chloroform–methanol–watermixture instead of detergent overcame
this difﬁculty. Signal assignment was achieved using standard TOCSY
and NOESY NMR experiments recorded at 800 MHz. All backbone HN
andHα resonances (except for Gly117)were assigned aswell asmost of
the side-chain protons. For all the peptides, the NOE patterns involving
the backbone protons display numerous αN (i, i+3) and αN (i, i+4)
NOEs (Fig. 3) which readily indicates a predominance of helical con-
formation. The structures of the peptides were determined using NOE
data recorded at 800MHz. For each peptide, the number of 1H–1H NOE
restraints used as distance restraints in the ﬁnal ARIA runs as well as
the structural statistics for the 10 selected structures is provided in
Table 2. Fig. 4 shows the overlays of the backbone of the resulting
ten energy-minimized structures for each of the ﬁve peptides. These
structures formed tight clusters with low backbone rmsd values indi-
cating that these parts of the peptide sequences arewell deﬁned. In the
case of P4, superposition of the backbone structures over a major
portion of the amino acid sequence was not successful. In contrast,
a satisfactory result was obtained by separately superposing two
stretches of 9 and 8 residues. Helical conformations were deﬁned from
the Ramachandran plots generated using the PROCHECK-NMR pro-
gram [18]. For all the peptides, helical regions involve major parts of
the hydrophobic amino acid sequences: V6 to Y24 for P1, A50 to E70 for
P2, M79 to A94 for P3, E104 to V129 for P4 and L137 to G160 for P5. In
the case of P3, the helix contains 16 of the 25 residues forming the
hydrophobic region. Our data therefore constitute the ﬁrst experimen-
tal result that supports a ﬁve-helix fold for TSPO. They also show that
the helical conformation of each transmembrane domain is mainly
formed through local short-range interactions.
Fig. 5. Far UV CD spectrum of mTSPO solubilized in DPC micelles in the absence (solid
line) and presence of the PK 11195 ligand (dotted line) recorded at 25 °C. The mTSPO
concentration was 40 μM in 10 mM Na phosphate buffer (pH 7.4), the PK 11195
concentration was 1.4 mM and the DPC concentration was 28.5 mM. Eight spectra were
recorded using a cell pathlength of 0.1 mm.
Fig. 6. Portion of the aliphatic region of the 1H spectrum of mTSPO in deuterated
DPC micelles in the absence (A) and presence of the PK 11195 ligand (B). Spectra
were acquired at 30 °C on a Bruker DRX 600 spectrometer using 0.2 mM mTSPO and
140 mMDPC concentration in 10 mM Na phosphate pH 6, the PK 11195 concentration
was 7 mM.
Fig. 4. Backbone traces of the 10 selected structures of the peptides P1 to P5.
Superposition of residues L11-F25 of P1, residues P51-E70 of P2, residues A78-W95 of
P3, residues W107-V115 of P4 (bottom left panel), residues V118-A125 of P4 (bottom
right panel) and residues P139-V154 of P5.
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tertiary fold
CD spectroscopy was used to investigate the secondary structure of
themouse recombinant TSPO (mTSPO) solubilized in DPCmicelles. The
corresponding spectrum (Fig. 5, solid line) exhibits three peaks at about
192, 209 and 221 nm that are characteristic of a high α-helical content.
Quantitative analysis of the CD spectrumwas performed using CDSSTR
and CONTINLL programs [25]. An average value of 45% helix content
was found. Considering that mTSPO contains ﬁve helices and that the
minimal length of each helix is 20-residues then the total number of
residues in helices is 100. As the N-terminal tag added for the protein
production includes 19 residues, the predicted helix content is thus 53%
for recombinant mTSPO. This predicted helix content is relatively close
to the helix content deduced from CD experiments.
In the second step, NMR experiments were performed to gain
insights into the tertiary fold of uniformly 15N labelled mTSPO in DPC
micelles. A well-known simple criterion to monitor the occurrence of
a stable tertiary structure is the presence of several methyl resonances
shifted at very low frequencies in the 1D 1H NMR spectrum. As seen in
Fig. 6A, such signal is not observed in the 1H NMR spectrum of mTSPOin DPC micelles, which indicates that the tertiary fold is not stable.
This observation is conﬁrmed by the spectral features of the
corresponding 2D 1H, 15N-HSQC spectra (Fig. 7 left): i) the spectral
dispersion, deﬁned as the difference Δ between the furthest upﬁeld
and downﬁeld resonances, of the amide proton resonances as well as
that of the Trp indole resonances (12 residues) appears dramatically
reduced, with Δ values of about 1 and 0.5 ppm respectively; ii) the
number of observed NH cross peaks is far fewer than the 212 expected
peaks: 188 peaks from amide nitrogen–proton pairs, 12 from the 12
Trp indole nitrogen–proton pair and 12 from the six Asn/Gln side-
chain amide groups.
Native-like secondary structure and the absence of stable tertiary
structure are characteristics of a molten globule frequently exhibiting
conformational exchanges that may lead to disappearance of NMR sig-
nals. Therefore, the conformational properties of mTSPO solubilized in
DPC micelles preclude an NMR study of its tertiary structure. Several
attempts to stabilize the tertiary fold ofmTSPOhavebeenundertaken. In
particular, other detergents have been tested such as sodium dodecyl
sulfate orn-dodecyl-β-D-maltoside at different concentrations butwith-
out success (unpublished data). Themost successful protocol was to add
the mTSPO high afﬁnity drug ligand PK 11195.
Fig. 7. 2D 1H, 15N-HSQC spectrum of mTSPO in deuterated DPC micelles in the absence (left) and presence of the PK 11195 ligand (right). Spectra were acquired at 30 °C on a Bruker
DRX 600 spectrometer using 0.2 mM mTSPO and 140 mM DPC concentration in 10 mM Na phosphate pH 6, the PK 11195 concentration was 7 mM.
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of its tertiary fold in the presence of the PK 11195 ligand
The effect of PK 11195 on the mTSPO secondary structure was
analyzed using CD spectroscopy. As shown in Fig. 5 (dotted line), the
presence of the PK 11195 ligand increases the helix content of mTSPO
from 45 to 52%, a value close to the predicted 53% helix content of the
protein. 1D 1H and 2D 1H, 15N-HSQC spectra of mTSPO were then
recorded in the presence of increasing drug to protein molar ratios.
Numerous upﬁeld methyl resonances up to −1 ppm were clearly de-
tected in the 1D 1H spectrum (Fig. 6B) for molar ratios greater than 10
in the presence of DPC detergent, which demonstrates the spectacular
stabilizing effect on the 3D mTSPO structure induced by PK 11195. As
shown in the 2D 1H, 15N-HSQC spectrum (Fig. 7, right) addition of a
large excess of PK 11195 induces a spectacular three-fold extent of the
spectral dispersion Δ relative to both the amide and Trp NH indole
signals, with Δ values of 3 and 1.4 ppm respectively. This result con-
ﬁrms that the mTSPO tertiary fold is stabilized by PK 11195 binding.
However, the drug to protein molar ratio required for stabilizing the
mTSPO 3D fold is indeed far from physiological conditions. In fact, as
shown in Materials and methods, the hydrophobic drug ligand PK
11195 interacts with detergent molecules and the large amount of DPC
(140mM) consequently reduces the free PK 11195 available for protein
3D fold stabilization.
4. Discussion
Understanding TSPO function at a molecular level, in particular the
mechanismof ligand activated cholesterol transport acrossmembrane,
will greatly beneﬁt from detailed structural data of the protein. Al-
though ﬁve transmembrane helical segments have been predicted for
the TSPO by sequence analysis and their topology have been proposed
using epitope insertions [5], no experimental structural data was
available. Moreover, there are no high resolution structural data avail-
able for a monomeric ﬁve-helix bundle transmembrane protein.
Structural properties of helical membrane proteins can be inves-
tigated by dissecting the primary sequence and studying the conforma-
tionalproperties of peptides encompassing thedifferent transmembrane
domains. To our knowledge, the dissection strategy has been applied
to ﬁve membrane proteins [26–31]. For three of these proteins, bac-
teriorhodopsin, rhodopsin and more recently the lactose permease
symporter, the crystal structures had previously been determined and
NMRexperiments have been recorded todetermine the 3D structure of
the isolated transmembrane domains. In general, the isolated peptidesthat retain a stable helical secondary structure adopt a conformation
close to the native one, although some tend to be frayed at the ends.
The two other studies concern membrane proteins of the GPCR su-
perfamily which have a seven-helix fold: the adenosine A2a receptor
[30] and the α-factor pheromone receptor [31] and provide structural
information that is relevant to the stability and assembly of these
receptors.
The case of TSPO appears thus singular since no crystal structure is
available and no known 3D fold architecture can be used as template.
Our NMR data show that the ﬁve designed peptides (P1 to P5, Fig. 4)
encompassing each of the ﬁve quasicontinuous sets of consecutive
hydrophobic residues (see Fig. 2) exhibit a stable helical structure. They
can be gathered into two groups.
The ﬁrst group includes P1, P2 and P4 that form stable helices in
detergent micelles (dodecylphosphocholine). These helices comprise
most of the hydrophobic region. However, in the case of P4, two helical
stretches of residues are deﬁned instead of one due to the presence of
few NOE connectivities involving residues V115-S-G-V118. This lack of
NOE restraints could result from a local ﬂexible structure. Such ﬂexible
local conformation may not be observed in the whole protein as a
result of stabilizing tertiary interactions, and therefore may not ne-
cessarily correspond to native features.
The second group includes P3 and P5 that tend to aggregate in DPC
micelles thus precluding an NMR study. However, both peptides ex-
hibit a stable helical conformation in organic solvent. For the P3
peptide, the presence of a doublet of proline is probably responsible
for the helix stop within the hydrophobic region as seen from NMR
data in organic solvent (Fig. 4). Since fully folded transmembrane helix
including a P–P motif has been found in membrane protein structures
[32], the helix interruption observed for the isolated P3 peptide may
not necessarily correspond to a native feature.
Results gained from a CD spectrum of recombinant mTSPO show
the presence of mainly helical secondary structure and NMR studies of
isolated peptides reveal the presence of at least ﬁve helical trans-
membrane segments. The addition of high afﬁnity mTSPO drug ligand
increases the percentage of helical secondary structure and strongly
stabilizes the protein tertiary fold as observed on CD (Fig. 5) and NMR
(Figs. 6 and 7) spectra, respectively. In the absence of these inter-
actions, CD and NMR data only detect the presence of secondary
structure formTSPO as observed in the case of themolten globule case.
The formation of a stable 3D fold is probably hindered by the insertion
of detergent molecules within the protein core or more generally
because micelles constitute a highly dynamic system that strongly
enhances inter-helix relativemovements as compared to a bilayer [33].
1381S. Murail et al. / Biochimica et Biophysica Acta 1778 (2008) 1375–1381Our study provides the ﬁrst experimental evidence for a ﬁve-helix
fold of TSPO and shows that each transmembrane domain constitutes
an autonomous folding unit. Our data show that, in micelles, the
mouse recombinant mTSPO exhibits helix content close to what is
expected but with an unstable tertiary fold. They reveal that the
binding of a drug ligand that stimulates cholesterol translocation is
able to strongly stabilize the mTSPO tertiary structure.
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